

Fabio Corrã

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5651588/publications.pdf>

Version: 2024-02-01

11
papers

424
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

997
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. <i>Cancers</i> , 2019, 11, 483.	3.7	107
2	The Network of Non-coding RNAs in Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 327.	2.8	96
3	SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?. <i>High-Throughput</i> , 2018, 7, 34.	4.4	48
4	Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. <i>Frontiers in Genetics</i> , 2018, 9, 174.	2.3	46
5	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	37
6	Profiling of the Predicted Circular RNAs in Ductal In Situ and Invasive Breast Cancer: A Pilot Study. <i>International Journal of Genomics</i> , 2016, 2016, 1-7.	1.6	30
7	Loss of miR-204 expression is a key event in melanoma. <i>Molecular Cancer</i> , 2018, 17, 71.	19.2	25
8	Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts. <i>Biomarker Research</i> , 2018, 6, 31.	6.8	17
9	Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA. <i>Amino Acids</i> , 2019, 51, 1273-1288.	2.7	7
10	Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 1-14.	6.4	6
11	UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. <i>Genes</i> , 2021, 12, 1978.	2.4	5